Patrys Limited - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Patrys Limited - Product Pipeline Review - 2015', provides an overview of the Patrys Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Patrys Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Patrys Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Patrys Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Patrys Limited's pipeline products Reasons to Buy - Evaluate Patrys Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Patrys Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Patrys Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Patrys Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Patrys Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Patrys Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 Patrys Limited Snapshot 5 Patrys Limited Overview 5 Key Information 5 Key Facts 5 Patrys Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Patrys Limited - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Patrys Limited - Pipeline Products Glance 11 Patrys Limited - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Patrys Limited - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Patrys Limited - Drug Profiles 15 PATSM-6 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 PAT-SC1 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PAT-LM1 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PATNM-1 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PATNM-3 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Antibodies for Cancer 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Cell Therapy for Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibodies for Cancer 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 PATH-12 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 PATSM-1 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 PATSM-3 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 PATSM-4 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 PATSM-5 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Patrys Limited - Pipeline Analysis 30 Patrys Limited - Pipeline Products by Target 30 Patrys Limited - Pipeline Products by Route of Administration 31 Patrys Limited - Pipeline Products by Molecule Type 32 Patrys Limited - Pipeline Products by Mechanism of Action 33 Patrys Limited - Recent Pipeline Updates 34 Patrys Limited - Dormant Projects 42 Patrys Limited - Locations And Subsidiaries 43 Head Office 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Patrys Limited, Key Information 5 Patrys Limited, Key Facts 5 Patrys Limited - Pipeline by Indication, 2015 8 Patrys Limited - Pipeline by Stage of Development, 2015 9 Patrys Limited - Monotherapy Products in Pipeline, 2015 10 Patrys Limited - Phase II, 2015 11 Patrys Limited - Phase I, 2015 12 Patrys Limited - Preclinical, 2015 13 Patrys Limited - Discovery, 2015 14 Patrys Limited - Pipeline by Target, 2015 30 Patrys Limited - Pipeline by Route of Administration, 2015 31 Patrys Limited - Pipeline by Molecule Type, 2015 32 Patrys Limited - Pipeline Products by Mechanism of Action, 2015 33 Patrys Limited - Recent Pipeline Updates, 2015 34 Patrys Limited - Dormant Developmental Projects,2015 42
List of Figures
Patrys Limited - Pipeline by Top 10 Indication, 2015 7 Patrys Limited - Pipeline by Stage of Development, 2015 9 Patrys Limited - Monotherapy Products in Pipeline, 2015 10 Patrys Limited - Pipeline by Top 10 Target, 2015 30 Patrys Limited - Pipeline by Top 10 Route of Administration, 2015 31 Patrys Limited - Pipeline by Top 10 Molecule Type, 2015 32 Patrys Limited - Pipeline Products by Top 10 Mechanism of Action, 2015 33
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...October 30, 2015
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...October 12, 2015
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...October 6, 2015
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...October 6, 2015
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...November 2, 2015
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-202-9519
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.